VolitionRX (VNRX)

• Market cap: $73.8M
• 1 day: -0.35%
• 5 days: -0.15%
• 1 month: -8.59%
• 3 months: 41.51%
• 6 months: 19.23%
• Year to date: 8.83%
• 1 year: 7.80%
• 5 years: -80.47%
• 10 years: -78.17%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Employees: 52

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

52% more capital invested

Capital invested by funds: $12M [Q1] → $18.2M (+$6.24M) [Q2]

12% more funds holding

Funds holding: 25 [Q1] → 28 (+3) [Q2]

1.37% more ownership

Funds ownership: 21.89% [Q1] → 23.27% (+1.37%) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 338% upside
• Avg. target: $4 483% upside
• High target: $5 629% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert	629% upside $5	Buy Maintained	15 Aug 2025
Jones Trading Justin Walsh	338% upside $3	Buy Initiated	10 Jun 2025